Randomized phase II trial of sequential versus concurrent docetaxel and PS-341 (NSC 681239, IND 58443) [bortezomib] in previously treated non-small cell lung cancer

Trial Profile

Randomized phase II trial of sequential versus concurrent docetaxel and PS-341 (NSC 681239, IND 58443) [bortezomib] in previously treated non-small cell lung cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs Bortezomib (Primary) ; Docetaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 20 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Sep 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 07 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top